| Serial Number | 79206752 |
| Word Mark | MABFC |
| Filing Date | Wednesday, December 14, 2016 |
| Status | 709 - CANCELLED - SECTION 71 |
| Status Date | Friday, September 20, 2024 |
| Registration Number | 5415118 |
| Registration Date | Tuesday, March 6, 2018 |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, December 19, 2017 |
| Description of Mark | The mark consists of the Greek letter delta to the left of the stylized term "MABFC", with the letters "M" and "F" capitalized and the remainder in lower case letters. |
| Goods and Services | Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Goods and Services | Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; platform technology, namely, protein expression platform for research and development of pharmaceuticals; platform technology, namely, protein expression platform for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; laboratory services in the field of monoclonal antibodies |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, September 20, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, September 20, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | FR |
| Party Name | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | FR |
| Party Name | LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | FR |
| Event Date | Event Description |
| Monday, May 8, 2017 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, May 8, 2017 | ASSIGNED TO EXAMINER |
| Thursday, May 11, 2017 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, May 18, 2017 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, May 4, 2017 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Wednesday, May 10, 2017 | NON-FINAL ACTION WRITTEN |
| Friday, May 12, 2017 | APPLICATION FILING RECEIPT MAILED |
| Thursday, May 18, 2017 | REFUSAL PROCESSED BY MPU |
| Saturday, June 3, 2017 | REFUSAL PROCESSED BY IB |
| Tuesday, October 24, 2017 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, November 29, 2017 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, November 29, 2017 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, November 29, 2017 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, December 15, 2017 | NOTIFICATION PROCESSED BY IB |
| Tuesday, December 19, 2017 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 19, 2017 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 6, 2018 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, June 6, 2018 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, June 8, 2018 | GENERIC MADRID TRANSACTION CREATED |
| Friday, November 3, 2017 | ASSIGNED TO LIE |
| Tuesday, November 14, 2017 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, November 14, 2017 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, November 15, 2017 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, June 8, 2018 | GENERIC MADRID TRANSACTION SENT TO IB |
| Friday, August 17, 2018 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Friday, March 5, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Saturday, April 3, 2021 | CORRECTION TRANSACTION RECEIVED FROM IB |
| Friday, April 9, 2021 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, March 6, 2023 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Friday, September 20, 2024 | CANCELLED SECTION 71 |
| Tuesday, May 20, 2025 | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED |
| Monday, April 26, 2021 | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Saturday, May 4, 2024 | NEW REPRESENTATIVE AT IB RECEIVED |